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Edited by Laszlo NagyAbstract Obesity-linked diseases are associated with sup-
pressed endothelial progenitor cell (EPC) function. Adiponectin
is an adipose-derived protein that is downregulated in obese
and diabetic subjects. Here, we investigated the eﬀects of adipo-
nectin on EPCs. EPC levels did not increase in adiponectin deﬁ-
cient (APN-KO) in response to hindlimb ischemia. Adenovirus-
mediated delivery of adiponectin increased EPC levels in both
WT and APN-KO mice. Incubation of human peripheral blood
mononuclear cells with adiponectin led to an increase of the num-
ber of EPCs. Adiponectin induced EPC diﬀerentiation into net-
work structures and served as a chemoattractant in EPC
migration assays. These data suggest that hypoadiponectinemia
may contribute to the depression of EPC levels that are observed
in patients with obesity-related cardiovascular disorders.
 2008 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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cell1. Introduction
Angiogenesis plays a crucial role in the tissue damage fol-
lowing ischemia. Circulating endothelial progenitor cells
(EPCs) exist in blood stream and migrate to sites of ischemia
where they contribute to blood vessel formation [1]. Obesity-
linked diseases including type 2 diabetes, dyslipidemia and
hypertension are associated with impaired EPC function [2–
4]. EPC mobilization in response to wounding is impaired in
diabetic mice [5], and glucose-intolerant individuals exhibit
lower levels of circulating EPCs [6]. However, the molecular
links between metabolic dysfunction and EPCs have not been
clariﬁed at the molecular level.
Adiponectin is an adipose-derived protein, which plays a
protective role in the development of obesity-linked diseases
[7]. A number of experimental studies show that adiponectin
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and impaired endothelium-dependent vasodilation (reviewed
in [7]). It has also been reported that adiponectin exerts favor-
able eﬀects on angiogenesis. We have shown that adiponectin
deﬁciency contributes to impaired angiogenic responses in
ischemic hindlimb or heart, whereas adenovirus-mediated
delivery of adiponectin promotes ischemia-mediated neovascu-
larization [8,9]. Adiponectin supplementation has also been
shown to stimulate blood vessel growth in both mouse Matri-
gel plug implantation and rabbit corneal angiogenesis models
[10]. Here, we examined the eﬀect of adiponectin on EPC level
and functions that are associated with angiogenesis.2. Materials and methods
2.1. Materials
Bacterially-produced mouse adiponectin was prepared as described
previously [10]. The adenoviral vectors expressing b-galactosidase
(Ad-bgal) or murine adiponectin (Ad-APN) from the cytomegalovirus
promoter/enhancer have been described previously [11]. DiI-Ac-LDL
and FITC-conjugated lectin were obtained from Biomedical Technol-
ogies (Waltham, MA). Human recombinant VEGF was purchased
from Roche (Indianapolis, IN).
2.2. Animals
Adiponectin-KO (APN-KO) and wild-type (WT) mice in a C57/BL6
background were used for this study [12]. Study protocols were ap-
proved by the Institutional Animal Care and Use Committee at Boston
University School of Medicine and Nagoya University. Mice at the
ages of 8–11 weeks were subjected to unilateral hind limb surgery un-
der anesthesia with sodium pentobarbital (50 mg/kg intraperitoneally).
The entire left femoral artery and vein were excised surgically in this
model [9]. In some experiments, 2 · 108 plaque-forming units (pfu)
of Ad-APN or Ad-bgal were injected into the jugular vein of APN-
KO mice 3 days prior to the hindlimb ischemia surgery. Mouse periph-
eral blood and bone marrow were obtained on postoperative day 7.
2.3. Cell culture of endothelial progenitor cells
Human peripheral blood mononuclear cells (PBMC) were isolated
employing a Histopaque density gradient procedure as described pre-
viously [13]. Cells were seeded on ﬁbronectin-coated dishes and cul-
tured in endothelial cell growth medium-2. Some experiments were
performed by the addition of 30 lg/ml of recombinant adiponectin
protein or bovine serum albumin (BSA) as control.
2.4. Cell mobilization assay in mice hindlimb ischemia model
Mouse MNCs were seeded on ﬁbronectin-coated dishes and cultured
in endothelial cell growth medium-2 for 5 days. EPCs were assessed by
co-staining with DiI-Ac-LDL and FITC-conjugated Lectin. After
staining, cells were quantiﬁed by examining 15 random microscopic
ﬁelds and double-positive cells as EPCs were counted. The expressionblished by Elsevier B.V. All rights reserved.
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marrow were assessed by FACS analysis as described previously [14].
MNCs were incubated with Sca-1 FITC and Flk-1 PE for 30 min.
FACS analysis was performed using a FACS Calibur instrument
and Cell Quest software (BD Biosciences).
2.5. Human EPC culture assay and ﬂow cytometry
Five days after culture, human EPCs were assayed by co-staining
with DiI-Ac-LDL and FITC-conjugated Lectin. After staining, cells
were quantiﬁed by examining 15 random microscopic ﬁelds and dou-
ble-positive cells were counted. FACS was used to detect the expres-
sion of the VEGF receptor, Flk-1, CD31 and CD45.
2.6. Tube formation assay and EPC incorporation
The formation of vascular-like structures by EPC on growth factor-
reduced Matrigel (BD Biosciences, Bedford, MA) was performed
according to the manufacturers instructions. EPCs or HUVEC were
seeded on coated plates at 3 · 104 cells/cm2 in EGM-2 medium contain-
ing adiponectin or BSA (30 lg/ml) and incubated at 37 C for 24 h. Net-
work formation was assessed using an inverted phase contrast
microscope (Nikon, Tokyo, Japan). In some experiments, EPC incor-
poration was assessed by seeding HUVEC and DiI-Ac-LDL labeled
EPC at a ratio of 1:1 onMatrigel [15]. Network formation was assessed
using a ﬂuorescence microscope to assess the frequency of labeled cell
incorporation. The degree of tube formation was quantiﬁed by measur-
ing the length of tubes in ﬁve random low power ﬁelds.
2.7. Migration assay
EPC migration was measured using a modiﬁed Boyden chamber as-
say (ChemoTx plate, Neuroprobe Inc., Gaithersburg, MD) as de-
scribed previously [16]. EPC were cultured with Adiponectin or BSA
(30 lg/ml) for 4 days and then labeled with Dil-Ac-LDL (10 lg/ml)
for 3 h. Cells were resuspended, and the labeled cell suspension was ap-
plied to the top of the ﬁlter. Adiponectin (30 lg/ml), VEGF (20 ng/ml)
or bovine serum albumin (BSA) (30 lg/ml) in phenol red free EBM
were added into the lower chamber and incubated for 12 h. EPCs
migrating through the ﬁlter into the chambers were determined with
the microplate ﬂuorometer.
2.8. Statistical analysis
Data are presented as mean ± S.D. The mean value was compared
between two groups using an unpaired t-test. The comparison among
more than three groups was performed by analysis of variance (ANO-
VA) with Scheﬀes F-test. A value of P < 0.05 was accepted as statisti-
cally signiﬁcant. All analyses were performed using Stat View-J
(version 5.0; SAS Institute Inc.).3. Results
3.1. Genetic manipulation of APN inﬂuences EPC levels in mice
We have shown that APN-KO mice are impaired in hind-
limb perfusion after ischemia [9]. Thus, we investigated EPC
levels in WT and APN-KO mice using the colony formation
assay. EPCs in PBMCs were initially identiﬁed by staining
with DiI-Ac-LDL and lectin [1]. As shown in Fig. 1a, no dif-
ferences were detected in EPC levels between WT and APN-
KO mice before ischemia surgery. However, 7 days after the
induction of ischemia, the number of EPCs derived from
WT mice increased signiﬁcantly, whereas APN-KO mice
showed little increase or no increase in EPC levels in response
to injury. To corroborate these ﬁndings, we analyzed EPC lev-
els in peripheral blood and bone marrow by ﬂow cytometry. In
this assay, EPCs were identiﬁed as Sca-1/Flk-1 positive cells.
Sham-treated WT and APN-KO mice displayed similar levels
of circulating Sca-1/Flk-1 positive cells (Fig. 1b). However,
the number of Sca-1/Flk-1 positive cells were signiﬁcantly low-
er in APN-KO mice than in WT mice on day 7 after hindlimb
ischemia.To conﬁrm that the impaired EPC response to ischemia was
a result of adiponectin deﬁciency, WT and APN-KO mice were
transduced with an adenoviral vector expressing adiponectin
(Ad-APN) or with a control adenovirus (Ad-bgal) delivered
through the jugular vein 3 days before hindlimb surgery. Ade-
novirus-mediated delivery of adiponectin via this method re-
sults in a 3.2-fold increase in circulating adiponectin in WT
mice (data not shown). Adiponectin-treated WT mice showed
a signiﬁcant increase in the number of Sca-1/Flk-1 positive
cells on 7 days after hindlimb surgery compared with control
mice that were treated with Ad-bgal. Treatment with Ad-
APN also increased the number of Sca-1/Flk-1 positive cells
both in peripheral blood and bone marrow in APN-KO mice
to levels similar to those to control mice (Fig. 1c). Adiponectin
deﬁciency did not aﬀect the frequency of Sca1+ cells in bone
marrow that were positive for markers of cell proliferation
or apoptosis (data not shown). Collectively, these data are con-
sistent with the hypothesis that adiponectin increases EPC lev-
els, perhaps through mobilization from the bone marrow.3.2. Eﬀect of adiponectin on EPC diﬀerentiation in vitro
To investigate the eﬀect of adiponectin on EPC diﬀerentia-
tion, human PBMCs were cultured in the presence or absence
of physiological levels of recombinant adiponectin protein. As
shown in Fig. 2a and b, the number of EPCs, as determined by
DiI-Ac-LDL/lectin double-positive cells, was signiﬁcantly in-
creased by treatment with adiponectin after 5 days in culture.
Treatment of cells with an equivalent amount of BSA protein
had no eﬀect on the number of DiI-Ac-LDL/lectin double-po-
sitive cells.
To corroborate these ﬁndings, cells cultured in the presence
of adiponectin or BSA were quantiﬁed for Flk-1 or CD31 cell
surface expression by ﬂow cytometric procedures (Fig. 2c).
Adiponectin-treatment led to a signiﬁcant increase in the
expression of these endothelial cell marker proteins compared
with PBMCs that were treated with BSA (Fig. 2d). Freshly iso-
lated mononuclear fractions express CD45, a common leuko-
cyte antigen, in addition to endothelial cell markers, but
CD45 expression is lost when cells are cultured in the presence
of VEGF [13,17]. Accordingly, after 5 days in culture few cells
expressed CD45, and the expression of this marker did not in-
crease in the presence of adiponectin.3.3. Eﬀect of adiponectin on EPC function in vitro
The eﬀects of adiponectin on EPC function were investigated
using the Matrigel network-formation assay. Treatment with
adiponectin promoted the formation of network structures
when EPCs or HUVECs were plated on Matrigel matrix
(Fig. 3a and b). Fig. 3c shows representative photographs of
co-cultured HUVECs and DiI-Ac-LDL–labeled EPCs on a
Matrigel matrix. Incorporation of EPCs into network struc-
tures was signiﬁcantly enhanced in the presence of adiponectin
(Fig. 3d). Furthermore, the total number of network projec-
tions per microscopic ﬁeld was signiﬁcantly higher when EPCs
were co-cultured with HUVECs in the presence of adiponectin
(Fig. 3e).
Cellular migration is required for vascular network forma-
tion. Therefore, we examined the eﬀect of adiponectin on uni-
directional migration of DiI-Ac-LDL-labeled EPCs using a
modiﬁed Boyden chamber assay. As shown in Fig. 3f, inclu-
sion of adiponectin in the lower chamber led to a signiﬁcant
ab
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Fig. 1. Eﬀect of adiponectin on EPC levels in mice. (a) Quantitative analysis of the number of DiI-Ac-LDL/lectin double-positive cells in cultured
PBMC from WT (n = 5) and APN-KO mice (n = 5) on day 7 after hindlimb ischemia or sham operation. (b) Quantitative analysis of the number of
Sca-1/Flk-1 positive cells in peripheral blood and bone marrow from WT and APN-KO mice on day 7 after hindlimb ischemia surgery or sham
operation. (c) Quantitative analysis of the number of Sca-1/Flk-1 positive cells in peripheral blood and bone marrow from WT and APN-KO mice
administered Ad-bgal or Ad-APN on post-operative day 7. Results are presented as means ± S.D. *P < 0.05, **P < 0.01 vs. sham-operated WT mice,
respectively (n = 5).
R. Shibata et al. / FEBS Letters 582 (2008) 1607–1612 1609increase in migratory activity. The stimulation of migratory
activity by adiponectin was similar to that seen with recombi-
nant VEGF.4. Discussion
The present study demonstrates that adiponectin regulates
the level of circulating EPC, deﬁned as Sca-1+/Flk-1+ cells,
in response to ischemic injury. The number of EPCs derivedfrom APN-KO mice was signiﬁcantly reduced compared to
WT mice under conditions of hindlimb ischemia. Conversely,
delivery of Ad-APN increased EPCs levels in response to ische-
mia in both WT and APN-KO mice. Adiponectin deﬁciency or
overexpression also modulated levels of Sca-1+/Flk-1+ cells in
bone marrow in a negative or positive manner, respectively.
Because increasing evidence suggests that bone marrow de-
rived EPCs signiﬁcantly contribute to cardiovascular function,
these data indicate that hypo-adiponectinemia might contrib-
ute to vascular deﬁciency through impaired EPC mobilization.
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Fig. 2. Adiponectin promotes EPC diﬀerentiation. Representative photographs of human EPCs, as determined by DiI-Ac-LDL/lectin double-
positive cell staining, in the presence or absence of 30 lg/ml recombinant adiponectin protein. Cells were analyzed on day 5 of ex vivo culture. (b)
Quantitative analysis of the number of DiI-Ac-LDL/lectin double-positive cells on day 5 of ex vivo culture. (c) Expression of Flk-1 and CD31
assessed by ﬂuorescence FACS. EPCs were isolated from human MNCs on day 5 of ex vivo culture. (d) Quantitative analysis of Flk-1 and CD31
expression assessed by ﬂuorescence FACS. Results are presented as means ± S.D. **P < 0.01 vs. BSA, respectively (n = 3–5).
1610 R. Shibata et al. / FEBS Letters 582 (2008) 1607–1612Consistent with this hypothesis, Matsuo et al. have shown that
plasma adiponectin levels are associated with EPC number in
patients with coronary artery disease [18].The present study shows that adiponectin can stimulate
the expression of the endothelial cell marker proteins Flk-1
and CD31 in cultured progenitor cell populations. Adipo-
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Fig. 3. Adiponectin promotes EPC function. (a) Representative phase contrast images are shown of cultured EPCs or HUVECs in the presence of
adiponectin or BSA. (b) Quantitative analysis of network projections formed on Matrigel for each experimental group. (c) Representative phase
contrast and ﬂuorescent images are shown of HUVECs co-cultured for 24 h with EPCs tagged with DiI-Ac-LDL isolated from human MNCs. (d)
Quantitative analysis of the number of EPCs incorporated into HUVECs on Matrigel. (e) Quantitative analysis of network projections formed on
Matrigel for each experimental group. (f) EPC migration assay was performed using a modiﬁed Boyden chamber using BSA (control) adiponectin or
VEGF in the lower chamber. Results are presented as means ± S.D. **P < 0.01 vs. BSA, respectively (n = 3–5).
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tive cells in cultures of PBMCs. It should be noted that
although EPCs are typically deﬁned by their ability to ex-
press Flk-1 and CD31, or the ability of DiI-Ac-LDL and
lectin uptake, these markers or features are not necessarily
unique for EPCs [19]. In addition, adiponectin stimulated
PBMC incorporation into developing endothelial cell net-
works in vitro, and served as a chemoattractant in a Boyden
chamber migration assay. Thus, it appears that adiponectin
can directly act on the EPC fraction of PBMC to promote
diﬀerentiation and function.
While it is clear that adiponectin increases circulating EPC
levels in mice, we cannot conclude from our studies that this
increase results from the mobilization of progenitor cells frombone marrow. In our experiments, ischemia led to an increase
in Sca-1/Flk-1-positive cells in both bone marrow and periph-
eral blood. It is possible that serial measurements in the bone
marrow and peripheral blood would reveal diﬀerent peak
points of progenitor cell accumulation in these two compart-
ments, which could be indicative of a mobilization mechanism.
Our experiments did not detect diﬀerences in the low rates of
proliferation or apoptosis in Sca1+ cells in bone marrow be-
tween wild-type and adiponectin-deﬁcient mice. Thus, the
adiponectin-mediated increase in circulating EPC levels may
occur through its ability to promote progenitor cell diﬀerenti-
ation. While this hypothesis is supported by our in vitro data,
further studies will be required to ascertain the mechanism by
which adiponectin increases circulating EPC levels in vivo.
1612 R. Shibata et al. / FEBS Letters 582 (2008) 1607–1612Consistent with the ﬁndings reported here, it has been shown
that adiponectin stimulates nitric oxide production in endothe-
lial cells through AMPK-dependent and AMPK-independent
phosphorylation of endothelial nitric oxide synthase eNOS
[10,20]. Because eNOS is required for the mobilization of EPCs
[5,21], adiponectin may aﬀect EPC action through its ability to
stimulate eNOS activity in these cells. In addition, PPARc
agonists are reported to increase the number and function of
EPCs in patients with type II diabetes and coronary artery dis-
ease [22,23]. Plasma adiponectin levels have been shown to be
increased by PPARc agonist treatment, and this upregulation
contributes to improved insulin sensitivity [22,24]. Thus, in
light of the data reported here, it is tempting to speculate that
the favorable eﬀects of PPARc agonists on EPC number and
function may be mediated in part by the action of these drugs
on adiponectin expression.
Taken together, these data provide evidence for a novel adi-
pocyte–bone marrow-signaling axis in EPC regulation that
could inﬂuence vascular remodeling. These ﬁndings provide a
plausible molecular mechanism linking dysregulated angiogen-
esis to diabetes and other obesity-related diseases that are asso-
ciated with hypoadiponectinemia. Thus, therapeutic
approaches aimed at increasing adiponectin production could
be useful for treating diseases associated with vascular insuﬃ-
ciency.
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